

Table.1

Patients	n=1025
Age, yr, (IQR)	69(61-74)
Male/female, n	741/296
Antithrombotic therapy, n	184(18.0%)
Antiplatelet therapy, n	104(10.1%)
Aspirin	57(5.6%)
Cilostazol	15(1.5%)
Thienopyridine	21(2.1%)
Doublet therapy	11(1.1%)
Anticoagulant therapy, n	70(6.9%)
Anticoagulant and antiplatelet therapy, n	10(1.0%)
Inflammatory bowel disease	11(1.1%)
Charlson comorbidity index, (IQR)	4(2-5)
Polyps	n=3163
Median lesion size, mm, (IQR), (range)	6 (5-8), (2-35)
Morphology	
0-Ip	173(5.4%)
0-Isp	295(9.3%)
0-Is	1606(50.7%)
0-IIa	1060(33.5%)
0-IIa+IIc	29(0.9%)
Resection methods	
CSP	704(22.2%)
EMR/HSP	2145(67.8%)
UEMR	314(9.9%)
Clip closure	2399(75.7%)
Location	
Right	1808(57.2%)
Left/Rectum	1355(42.8%)
Histology	
Adenoma	2463(77.9%)
Mucosal carcinoma (Tis)	42(1.3%)

(T1)	Carcinoma with submucosal invasion	14(0.4%)
	Serrated lesion	500(15.8%)
	Others	136(4.3%)
	Follow-up CS	1684(53.2%)
	Recurrence	5(0.3%)
	Adversed events	1684(53.2%)
	Delayed bleeding	8(0.3%)
	Perforation	2(0.06%)

Note:CSP,cold snare polypectomy; EMR,endoscopic mucosal resection;
HSP,hot snare polypectomy; UEMR,underwater endoscopic mucosal resection

Table.2

Delayed bleeding	Events (n=8)	Patients (n=1025)	<i>P</i> value
Age >70	4	470	0.34
Male	6	741	0.53
Antithrombotic therapy			
Antiplatelet therapy	0	114	0.31
Anticoagulant therapy	3	70	0.0017
Charlson comorbidity index >5	4	323	0.26
Inflammatory bowel disease	2	9	<0.001

Table.3

Delayed bleeding	Events (n=7)	Polyps (n=3163)	<i>P</i> value
Lesion size			0.29
<6 mm	1 (0.06%)	1516	
6 ≤, <10 mm	3 (0.3%)	958	
10 ≤, <20 mm	3 (0.5%)	662	
20 ≤ mm	0(0%)	27	
Morphology			0.35
0-Ip, 0-Isp, 0-Is	4 (0.2%)	2075	
0-IIa, 0-IIa+IIc	3 (0.3%)	1078	
Resection methods			0.15
CSP	0 (0%)	704	
EMR/HSP	5 (0.2%)	2140	
UEMR	2 (0.6%)	312	
Clip closure			
Performed	5 (0.2%)	2396	0.78
Location			
Right	5 (0.3%)	1808	0.43
Histology			0.87
Adenoma	6 (0.2%)	2464	
Carcinoma	0 (0%)	228	
Serrated lesion	1 (0.3%)	314	
Others	0 (0%)	157	

Note: One case which had undergone multiple polypectomy, the source of the bleeding was not detailed.

Table.4

	CSP	EMR/HSP	UEMR	<i>P</i> value
Cases	704(22.2%)	2145(67.8%)	314(9.9%)	
Lesion size, mm (IQR)	4 (3-5)	6 (5-8)	7 (6-10)	<0.01
Delayed bleeding	0(0%)	5(0.2%)	2(0.6%)	0.15
Lesion size				
<6 mm	0/563(0%)	1/879(0.1%)	0/74(0%)	0.69
6 ≤ , <10 mm	0/128(0%)	1/690(0.2%)	1/140(0.7%)	0.34
10 ≤ , <20 mm	0/13(0%)	3/549(0.6%)	1/100(1%)	0.83
20 ≤ mm	0/0	0/26(0%)	0/0	-
Perforation	0(0%)	2(0.1%)	0(0%)	0.62
Lesion size				
<6 mm	0/563(0%)	0/879(0%)	0/74(0%)	-
6 ≤ , <10 mm	0/128(0%)	0/690(0%)	0/140(0%)	-
10 ≤ , <20 mm	0/13(0%)	2/549(0.4%)	0/100(0%)	0.81
20 ≤ mm	0/0	0/26(0%)	0/0	-
En bloc resection	704(100%)	2083(97.1%)	305(97.1%)	<0.01
Follow up CS	330	1128	226	
Recurrence	1(0.3%)	1(0.09%)	3(1.3%)	<0.01
Lesion size				
<6 mm	1/261(0.4%)	0/500(0%)	1/50(2%)	0.02
6 ≤ , <10 mm	0/64(0%)	1/347(0.3%)	1/105(1%)	0.54
10 ≤ , <20 mm	0/5(0%)	0/259(0%)	1/71(1.4%)	0.15
20 ≤ mm	0/0	0/22(0%)	0/0	-

Table.5

Cases	Location	Size (mm)	Morphology	Resection method	Histology	en bloc resection	R0 resection	Size of recurrence polyps (mm)	Morphology of recurrence polyps	Duration to recurrence (day)	additional resection method
1	R	12	IIa	UEMR	adenoma	Yes	No (HMX)	3	IIa	373	UEMR
2	T	7	IIa	EMR	serrated lesion	Yes	No (HMX)	9	IIa	364	EMR
3	T	5	IIa	UEMR	adenoma	Yes	No (HMX)	3	IIa	282	UEMR
4	A	12	IIa	UEMR	serrated lesion	Yes	No (HMX)	7	IIa	414	UEMR
5	T	5	IIa	CSP	serrated lesion	Yes	No (HMX)	4	IIa	364	UEMR

Table.6

	CSP	EMR/HSP	UEMR	p value
Number				
1st	117 (11.3%)	850 (82.4%)	65 (6.3%)	
2nd	160 (17.3%)	640 (69.1%)	126 (13.6%)	
3rd	422 (35.0%)	663 (55.0%)	120 (10.0%)	
Delayed bleeding				
1st	0/117 (0%)	4/850 (0.5%)	0/65 (0%)	0.65
2nd	0/160 (0%)	1/640 (0.2%)	1/126 (0.8%)	0.25
3rd	0/422 (0%)	1/663 (0.2%)	1/120 (0.8%)	0.15
Perforation				
1st	0/117 (0%)	0/850 (0%)	0/65 (0%)	-
2nd	0/160 (0%)	1/640 (0.2%)	0/126 (0%)	0.81
3rd	0/422 (0%)	1/663 (0.2%)	0/120 (0%)	0.65
Recurrence				
1st	0/85 (0%)	1/458 (0.2%)	2/51 (4.0%)	0.015
2nd	0/96 (0%)	0/364 (0%)	1/89 (1.1%)	0.07
3rd	1/149 (0.7%)	0/306 (0%)	0/86 (0%)	0.26

Note: 1st period: Apr. 2017 ~ Mar. 2018; 2nd period: Apr. 2018 ~ Mar. 2019; 3rd period: Apr. 2019 ~ Jun. 2020.